PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The Basel-based pharmaceutical company Roche increased group sales by 5 per cent in the first nine months of the year. The recently launched medicines Tecentriq, Ocrevus und Alecensa contributed strongly to this growth.
Roche’s Diagnostics and Pharmaceuticals Division each experienced sales growth of 5 per cent between January and September of this year. According to a Roche statement, sales in the Pharmaceutical Division reached 30.6 billion Swiss francs, compared to 29.1 billion in the same period last year. The three recently launched medicines Ocrevus, Tecentriq and Alecensa contributed 0.9 billion francs of the 1.5 billion francs in new sales.
Tecentriq was approved in the EU as a monotherapy for the treatment of a specific type of bladder cancer. Ocrevus was approved in Switzerland and the U.S. to treat both types of multiple sclerosis. Alecensa was granted approval in February in the EU for the treatment of people with locally advanced or metastatic non-small cell lung cancer who have been treated with chemotherapy.
For 2017, Roche expects sales to grow mid-single digit, at constant exchange rates.
“Based on the strong sales growth of our Pharmaceuticals and Diagnostics Divisions in the first nine months, I am confident that we will achieve our full-year targets. The growth is largely driven by new product launches,” CEO Severin Schwan, said in a statement.